The most useful thing about an opening plenary is usually not what gets said. It is who the organisers decided to put on...
Biopharmaceutical manufacturing is entering a period of significant change. With over 2000 biological therapeutics in de...
Rare diseases/orphan diseases affect a very small fraction of the population and are frequently debilitating. World Heal...
The global AI debate is often framed as a choice between acceleration and restraint: innovate first and regulate later, ...
Please share details of the current R&D projects of DNDi in India. What challenges are these projects addressing? O...
What are Caidya’s major highlights for 2026 that will strengthen its presence in the global CRO market? And what a...
How will the new investment accelerate the development of TAVST01? When do you plan to launch the product in the market?...
As healthcare systems across Southeast Asia embrace smarter technologies and new models of care, Taiwan is looking to de...
China’s biotech and pharmaceutical sector is entering a new phase of global relevance. A surge in out-licensing de...
How is Takeda’s partnership with Biological E. Limited playing a role in strengthening dengue vaccine access in In...
As cell therapies advance towards greater clinical sophistication and commercial scale, the focus is shifting fr...
In conversation with BioSpectrum Asia, Laurie Masiello and John Masiello, Co-Founders of Predictive Monitor, explore how...
Australia is rapidly evolving beyond its reputation as a destination for early-stage clinical trials to build a more com...
BIOSPECTRUM ASIA | EARNINGS ALERTS +35.2% 10.7 pt -15% EUR 0.15 Celltrion r...
How are Australia–India health partnerships driving innovations in the non-communicable diseases sector? We have ...
For decades, cancer treatment has largely focused on finding a single breakthrough therapy capable o...
On 29 September, the second compliance date under Proclamation 11020 arrives. From that moment, every pharmaceutical imp...
Healthcare delivery is undergoing structural reconfiguration. What began as a tactical response to hospital capacity pre...
The Asia-Pacific (APAC) region is entering a transformative era in cancer research. Governments are investing heavily in...
J-Pharma has built its pipeline around amino acid transporter (LAT1)-targeted therapies. What was the vision behind this...
Bispecific antibodies have transformed treatment by simultaneously targeting two molecules, delivering significant clini...
For patients living with a rare disorder, receiving an accurate diagnosis can take years. Misdiagnosis often leads to un...
Although each rare disease affects only a small number of people, collectively they represent one of the world's largest...
BioSpectrum Asia launched the APAC Bioeconomy Index 2026, the first independent, region-native benchmark of Asia-Pacific...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
